The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.

Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2002Cited by 61 (Europe PMC)

PMID12054164DOI10.1359/jbmr.2002.17.6.1081PepBankPUB-12054164

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with GH deficiency, GH increased osteocalcin versus controls in both sexes.
In plain wordsIn adults with GH deficiency, GH increased osteocalcin versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseOsteocalcin
Study
n = 100
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Source sentences
Summary
Despite a similar increase in parameters of bone turnover (osteocalcin [OC], procollagen type I carboxy-terminal propeptide [PICP], and pyridinolines ([PYD]) in male and female GH-treated patients compared with controls,
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416401
02HumanRandomized controlled trialEfficacy outcome
In adults with GH deficiency, GH increased PICP versus controls in both sexes.
In plain wordsIn adults with GH deficiency, GH increased PICP versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseProcollagen type I carboxy-terminal propeptide
Study
n = 100
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Source sentences
Summary
Despite a similar increase in parameters of bone turnover (osteocalcin [OC], procollagen type I carboxy-terminal propeptide [PICP], and pyridinolines ([PYD]) in male and female GH-treated patients compared with controls,
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416402
03HumanRandomized controlled trialEfficacy outcome
In adults with GH deficiency, GH increased pyridinolines versus controls in both sexes.
In plain wordsIn adults with GH deficiency, GH increased pyridinolines versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreasePyridinolines
Study
n = 100
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Source sentences
Summary
Despite a similar increase in parameters of bone turnover (osteocalcin [OC], procollagen type I carboxy-terminal propeptide [PICP], and pyridinolines ([PYD]) in male and female GH-treated patients compared with controls,
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416403
04HumanRandomized controlled trialEfficacy outcome
In men with GH deficiency, GH increased spine BMC by 6.8 +/- 1.1% at 24 months versus control evolution (p = 0.009).
In plain wordsIn men with GH deficiency, GH increased spine bone mineral content versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale spine bone mineral content
Study
n = 59
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Measurements
Spine BMC change
6.8%
male GH-treated vs controls, change at 24 months, SEM 1.1
Source sentences
Summary
A significant increase in spine BMC and BMD and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH-treated patients compared with the evolution in controls (mean +/- SEM change at 24 months: +6.8 +/- 1.1% and p = 0.009, +5.1 +/- 0.8% and p = 0.005, +3.5 +…
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416404
05HumanRandomized controlled trialEfficacy outcome
In men with GH deficiency, GH increased spine BMD by 5.1 +/- 0.8% at 24 months versus control evolution (p = 0.005).
In plain wordsIn men with GH deficiency, GH increased spine bone density versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale spine bone mineral density
Study
n = 59
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Measurements
Spine BMD change
5.1%
male GH-treated vs controls, change at 24 months, SEM 0.8
Source sentences
Summary
A significant increase in spine BMC and BMD and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH-treated patients compared with the evolution in controls (mean +/- SEM change at 24 months: +6.8 +/- 1.1% and p = 0.009, +5.1 +/- 0.8% and p = 0.005, +3.5 +…
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416405
06HumanRandomized controlled trialEfficacy outcome
In men with GH deficiency, GH increased total hip BMD by 3.5 +/- 0.7% versus control evolution (p = 0.02).
In plain wordsIn men with GH deficiency, GH increased hip bone density versus controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale total hip bone mineral density
Study
n = 59
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Measurements
Total hip BMD change
3.5%
male GH-treated vs controls, change at 24 months, SEM 0.7
Source sentences
Summary
A significant increase in spine BMC and BMD and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH-treated patients compared with the evolution in controls (mean +/- SEM change at 24 months: +6.8 +/- 1.1% and p = 0.009, +5.1 +/- 0.8% and p = 0.005, +3.5 +…
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416406
07HumanRandomized controlled trialEfficacy outcome
In men with GH deficiency, GH decreased ultradistal radius BMD by 2.6 +/- 0.8% versus control evolution (p = 0.008).
In plain wordsIn men with GH deficiency, GH decreased bone density at the ultradistal radius versus controls.
Peptide
HGH (somatotropin)
Outcome
DecreaseMale ultradistal radius bone mineral density
Study
n = 59
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Measurements
Ultradistal radius BMD change
−2.6%
male GH-treated vs controls, change at 24 months, SEM 0.8
Source sentences
Summary
A significant increase in spine BMC and BMD and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH-treated patients compared with the evolution in controls (mean +/- SEM change at 24 months: +6.8 +/- 1.1% and p = 0.009, +5.1 +/- 0.8% and p = 0.005, +3.5 +…
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416407
08HumanRandomized controlled trialEfficacy outcome
In women with GH deficiency, GH had no significant treatment effects on bone outcomes versus controls.
In plain wordsIn women with GH deficiency, GH had no significant effects on bone outcomes versus controls.
Peptide
HGH (somatotropin)
Outcome
No significant changeFemale bone treatment effects
Study
n = 41
Comparator
Untreated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.18 IU/kg per week · 24 monthsAs given in this study (human).
Source sentences
Summary
No significant treatment effects were observed in female patients.
1 context sentence(design, population, supporting numbers)
Summary · context
100 patients (59 men and 41 women), aged 25-65 years (mean, 49.7 years) with adult-onset GHD
Report a problemFND-1205416408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.